Search Result

Results for "

rectal cancer

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Antibiotic (1) Autophagy (3) Bacterial (1) Biochemical Assay Reagents (2) Ceramidase (2) Drug Metabolite (2) FAAH (2) Glutathione Peroxidase (2) Histone Demethylase (1) Isotope-Labeled Compounds (3) Nucleoside Antimetabolite/Analog (2) PARP (1) Reference Standards (4) SARS-CoV (2) Topoisomerase (3) Virus Protease (2)
By Research Areas:	Cancer (12) Infection (3) Inflammation/Immunology (2)

Inhibitors & Agonists

Screening Libraries

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: BCRP

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-16562A

Irinotecan hydrochloride 50+ Cited Publications (+)-Irinotecan hydrochloride; CPT-11 hydrochloride; VAL-413	Topoisomerase Autophagy	Cancer
Irinotecan hydrochloride ((+)-Irinotecan hydrochloride) is a topoisomerase I inhibitor mainly used to treat colon cancer and rectal cancer .

HY-126373

SN-38 glucuronide SN-38G	Drug Metabolite	Cancer
SN-38 glucuronide is an inactive metabolite of the anticancer active molecule Irinotecan (HY-16562) and has toxic effects on the gastrointestinal tract. Irinotecan is a topoisomerase I inhibitor which can be used for researching colon and rectal cancer .

HY-141436

Sucrosofate potassium Sucrose octasulfate potassium	Biochemical Assay Reagents	Cancer
Sucrosofate (Sucrose octasulfate) potassium is a sucrose acid that can be used to prepare liposomes to deliver Irinotecan (HY-16562). Irinotecan is an inhibitor of topoisomerase Topo I and is commonly used in colon and rectal cancer research. Sucrosofate nanoliposome preparation loaded with Irinotecan, also known as PEP02 or MM-398 .

HY-16562AR

Irinotecan hydrochloride (Standard) (+)-Irinotecan hydrochloride (Standard); CPT-11 hydrochloride (Standard); VAL-413 (Standard)	Reference Standards Topoisomerase Autophagy	Cancer
Irinotecan (hydrochloride) (Standard) is the analytical standard of Irinotecan (hydrochloride). This product is intended for research and analytical applications. Irinotecan hydrochloride ((+)-Irinotecan hydrochloride) is a topoisomerase I inhibitor mainly used to treat colon cancer and rectal cancer .

HY-16562AS

Irinotecan-d5 hydrochloride (+)-Irinotecan-d₅ hydrochloride; CPT-11-d₅ hydrochloride; VAL-413-d₅	Autophagy Topoisomerase Isotope-Labeled Compounds	Cancer
Irinotecan-d₅ hydrochloride is deuterated labeled Irinotecan hydrochloride (HY-16562A). Irinotecan hydrochloride ((+)-Irinotecan hydrochloride) is a topoisomerase I inhibitor mainly used to treat colon cancer and rectal cancer .

HY-16472R

Sulfacytine (Standard)	Reference Standards Antibiotic Bacterial	Infection
Irinotecan (hydrochloride) (Standard) is the analytical standard of Irinotecan (hydrochloride). This product is intended for research and analytical applications. Irinotecan hydrochloride ((+)-Irinotecan hydrochloride) is a topoisomerase I inhibitor mainly used to treat colon cancer and rectal cancer .

HY-N14993

3' -Deoxytalopiericidin	Others	Cancer
3'-Deoxytalopiericidin is found in the strain of Streptomyces sp.DO-100. 3'-Deoxytalopiericidin inhibited the activity of 26 cell in rectal cancer than L1210 cell in leukemia .

HY-126373S1

SN-38 glucuronide-13C6 SN-38G-¹³C₆	Isotope-Labeled Compounds	Others
SN-38 glucuronide- ¹³C₆ is the ¹³C labeled SN-38 glucuronide (HY-126373) . SN-38 glucuronide is an inactive metabolite of the cancer agent Irinotecan. Irinotecan is a topoisomerase I inhibitor which can be used for researching colon and rectal cancer .

HY-W653919

SN-38 glucuronide-d3	Isotope-Labeled Compounds Drug Metabolite	Cancer
SN-38 glucuronide-d₃ is deuterium labeled SN-38 glucuronide. SN-38 glucuronide is an inactive metabolite of the anticancer active molecule Irinotecan (HY-16562) and has toxic effects on the gastrointestinal tract. Irinotecan is a topoisomerase I inhibitor which can be used for researching colon and rectal cancer .

HY-160183

LSD1-IN-29	Histone Demethylase	Cancer
LSD1-IN-29 (compound 6) is a Lysine specific demethylase 1 (LSD1) inhibitor with the IC₅₀ of 19 nM .

HY-141436R

Sucrosofate potassium (Standard) Sucrose octasulfate potassium (Standard)	Biochemical Assay Reagents Reference Standards	Cancer
Sucrosofate (potassium) (Standard) is the analytical standard of Sucrosofate (potassium). This product is intended for research and analytical applications. Sucrosofate (Sucrose octasulfate) potassium is a sucrose acid that can be used to prepare liposomes to deliver Irinotecan (HY-16562). Irinotecan is an inhibitor of topoisomerase Topo I and is commonly used in colon and rectal cancer research. Sucrosofate nanoliposome preparation loaded with Irinotecan, also known as PEP02 or MM-398 .

HY-137849

RK-582	PARP	Cancer
RK-582 is an orally active, spiroindoline-based selective inhibitor of tankyrase. The IC₅₀s of RK-582 against TNKS1/PARP5A and PARP1 are 36.1 nM and 18.168 nM, respectively. RK-582 inhibits rectal cancer COLO-320DM cells (GI50=0.23 μM) and significantly inhibits tumor growth in a COLO-320DM mouse xenograft model .

HY-B0182

Carmofur 3 Publications Verification HCFU	Nucleoside Antimetabolite/Analog SARS-CoV Virus Protease FAAH Ceramidase Glutathione Peroxidase	Infection Inflammation/Immunology Cancer
Carmofur (HCFU) is a rat recombinant acid ceramidase inhibitor with an IC₅₀ of 29 nM. Carmofur is also a protease inhibitor of SARS-CoV-2 main protease (Mpro), fatty acid amide hydrolase (FAAH) and N-acylethanolamine acid amidase (NAAA). Carmofur has anti-cancer, anti-inflammatory and anti-virus activities, and can be used for the study of COVID-19 and acute lung injury (ALI) .

HY-B0182R

Carmofur (Standard) HCFU (Standard)	Reference Standards Nucleoside Antimetabolite/Analog SARS-CoV Virus Protease FAAH Ceramidase Glutathione Peroxidase	Infection Inflammation/Immunology Cancer
Carmofur (Standard) is the analytical standard of Carmofur. This product is intended for research and analytical applications. Carmofur (HCFU) is a rat recombinant acid ceramidase inhibitor with an IC₅₀ of 29 nM. Carmofur is also a protease inhibitor of SARS-CoV-2 main protease (Mpro), fatty acid amide hydrolase (FAAH) and N-acylethanolamine acid amidase (NAAA). Carmofur has anti-cancer, anti-inflammatory and anti-virus activities, and can be used for the study of COVID-19 and acute lung injury (ALI) .

Cat. No.	Product Name

HY-L103

Anti-Colorectal Cancer Compound Library	2,049 compounds
Colorectal cancer (CRC), also known as bowel cancer, colon cancer, or rectal cancer, arises as adenocarcinoma from glandular epithelial cells of the large intestine comprised of the colon and rectum. The majority of cases of CRC are sporadic and result from risk factors, such as a sedentary lifestyle, obesity, processed diets, alcohol consumption and smoking. CRC is also a common preventable cancer. Studies showed several cellular signaling pathways dysregulated in CRC, leading to the onset of malignant phenotypes. Therefore, it is necessary to analyze the signaling pathways involved in the occurrence and development of colorectal cancer to study the progression and drug treatment of colorectal cancer. Among them, Wnt/β-catenin, p53, TGF-β/SMAD, NF-κB, Notch, VEGF and other target genes and signaling pathways are the focus of research. MCE offers a unique collection of 2,049 compounds with identified and potential anti-colorectal cancer activity. MCE anti-colorectal cancer compound library is a useful tool for anti-colorectal cancer drugs screening and other related research.

Anti-Colorectal Cancer Compound Library

2,049 compounds

Colorectal cancer (CRC), also known as bowel cancer, colon cancer, or rectal cancer, arises as adenocarcinoma from glandular epithelial cells of the large intestine comprised of the colon and rectum. The majority of cases of CRC are sporadic and result from risk factors, such as a sedentary lifestyle, obesity, processed diets, alcohol consumption and smoking. CRC is also a common preventable cancer.

Studies showed several cellular signaling pathways dysregulated in CRC, leading to the onset of malignant phenotypes. Therefore, it is necessary to analyze the signaling pathways involved in the occurrence and development of colorectal cancer to study the progression and drug treatment of colorectal cancer. Among them, Wnt/β-catenin, p53, TGF-β/SMAD, NF-κB, Notch, VEGF and other target genes and signaling pathways are the focus of research. MCE offers a unique collection of 2,049 compounds with identified and potential anti-colorectal cancer activity. MCE anti-colorectal cancer compound library is a useful tool for anti-colorectal cancer drugs screening and other related research.

Cat. No.	Product Name	Category	Target	Chemical Structure